Miller Fisher−Guillain−Barré overlap syndrome during the Zika Virus outbreak

Wilma González–Barreto, Gloria M. Rodríguez–Vega, Patricia De Jesús–Umpierre, José R. Rodríguez–Vázquez


Miller Fisher is a variant of Guillain–Barré syndrome, presented mainly with ataxia, areflexia and ophthalmoplegia. After the 2016 Zika virus (ZIKV) outbreak, an association between Guillain–Barré syndrome and ZIKV was established. ZIKV is a mosquito–borne–flavivirus, considered a mild disease with symptoms including fever, rash, conjunctivitis, and arthralgia. Most of cases with ZIKV infection are asymptomatic, however in neurologic complications including Guillain–Barré syndrome, symptoms could evolve leading to fatalities. A case of Miller Fisher–Guillain–Barré overlap syndrome during the 2016 ZIKV outbreak is presented.


Miller Fisher–Guillain–Barré overlap syndrome; Miller Fisher variant; Guillain–Barré syndrome; Zika Virus infection; Puerto Rico

Full Text:



Dirlikov E, Ryff KR, Torres–Aponte J, et al. Update: Ongoing Zika virus transmission–Puerto Rico. MMWR Morb Mortal Wkly Rep 2016; 65(17):451–55.

Sharp TM, Muñoz–Jordán J, Perez–Padilla J, et al. Zika virus associated with severe thrombocytopenia. Clin Infect Dis 2016; 63(9):1198–1201.

Cao–Lormeau V, Blake A, Mons S, et al. Guillain–Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case–control study. Lancet 2016; 387(10027):1531-1539.

Hennessey M, Fischer M, Staples E. Zika virus spreads to new areas – region of the Americas, May 2015–January 2016. MMWR Morb Mortal Wkly Rep 2016; 65(3):55–58.

Yuki N, Hartung HP. Guillain-Barré syndrome. N Engl J Med 2012; 366(24):2294-2304.

Yepishin IV, Allison RZ, Kaminskas DA, Zagorski NM, Liow KK. Miller Fisher syndrome: A case report highlighting heterogeneity of clinical features and focused differential diagnosis. Hawaii J Med Public Health 2016; 75(7):196-199.

Dirlikov E, Major CE, Mayshack M, et al. Guillain-Barré syndrome during ongoing Zika Virus transmission – Puerto Rico, January 1–July 31, 2016. MMWR Morb Mortal Wkly Rep 2016; 65(34):910-914.

Dirlikov E, Kniss K, Major C, et al. Guillain–Barré syndrome and healthcare needs during Zika virus transmission, Puerto Rico, 2016. Emerg Infect Dis 2017; 23(1):134-136.

Salinas JL, Major CG, Pastula DM, et al. Incidence and clinical characteristics of Guillain–Barré syndrome before the introduction of Zika virus in Puerto Rico. J Neurol Sci 2017. doi: 10.1016/j.jns.2017.04.006

dos Santos T, Rodriguez A, Almiron M, et al. Zika virus and Guillain-Barré syndrome–Case series from seven countries. N Engl J Med 2016; 375:1598-1601.

Pan American Health Organization. Guidelines for surveillance of Zika virus disease and its complications. Washington, D.C.: PAHO, 2016. [ available at 26.12.2017]

Adams L, Bello–Pagán M, Lozier M, et al. Update: Ongoing Zika virus transmission – Puerto Rico. MMWR Morb Mortal Wkly Rep 2016; 65(30):774–779.

Rabe IB, Staples JE, Villanueva J, et al. Interim guidance for interpretation of Zika virus antibody test results. MMWR Morb Mortal Wkly Rep 2016; 65.

Guidance for U.S. Laboratory testing for Zika virus infection: Implications for health care providers. MMWR Morb Mortal Wkly Rep 2016; 65(46):1304.

Sever M, Aksay E, Gulec F. The diagnosis is made only with suspicion: Miller Fisher syndrome. Hong Kong Jour Emerg Med 2011; 18(6):428-431.

Wakerley BR, Yuki N. Mimics and chamaleons in Guillain–Barré and Miller Fisher syndromes. Pract Neurol 2015; 15(2):90-99.

Sejvar JJ, Hohl KS, Gidudu J, et al. Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011; 29:599–612.

Farmakidis C, Inan S, Milstein M, Herskovitz S. Headache and pain in Guillain–Barré syndrome. Curr Pain Headache Rep 2015; 19:40.

Pirotta T, Chircop C, Vella N. Is headache a common symptom in Miller Fisher syndrome? – two case reports. J Autoimmun Res 2016; 3(1):1011.

Friedman DI, Potts E. Headache associated with Miller Fisher syndrome. Headache 2007; 1347–1348.

Cherin P, Marie I, Michallet M, et al. Management of adverse events in the treatment of patients with immunoglubin therapy: A review of evidence. Autoimmun Rev 2015; 15(2016):71–81.

Odaka M, Yuki N, Hirata K. Anti–GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry 2001; 70:50–55.


Copyright (c) 2017 Wilma González–Barreto, Gloria M. Rodríguez–Vega, Patricia De Jesús–Umpierre, José R. Rodríguez–Vázquez

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975